FIELD: medicine.
SUBSTANCE: invention refers to a technique for detecting apoptosis in a mammal's cell wherein the apoptosis is initiated by death receptor 4, death receptor 5 or Fas.
EFFECT: invention provides apoptosis detection for the purpose of assessment of mammal's cancer cell sensitivity to apoptosis-inducing agents.
17 cl, 1 ex, 12 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| ANALYSES AND METHODS OF BIOMARKER APPLICATION | 2006 |
|
RU2409817C2 |
| ANALYSES AND METHODS USING BIOMARKERS | 2005 |
|
RU2410438C2 |
| ANALYSES AND METHODS WITH APPLICATION OF BIOMARKERS | 2005 |
|
RU2431676C2 |
| DR5 ANTIBODIES AND USE THEREOF | 2006 |
|
RU2458072C2 |
| METHOD OF PURIFYING APO-2 LIGAND/TRAIL VIA COLD CRYSTALLISATION | 2006 |
|
RU2435781C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
